Page last updated: 2024-08-21

indazoles and Neuroendocrine Tumors

indazoles has been researched along with Neuroendocrine Tumors in 11 studies

Research

Studies (11)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	11 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bao, F; Christiansen, J; Foley, P; Hornby, Z; Luo, D; Maneval, EC; Multani, P; Sigal, D; Tartar, M; Xavier, M	1
Ahn, HK; Choi, JY; Choi, SH; Kang, WK; Kim, H; Kim, KM; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS	1
Raj, N; Reidy-Lagunes, D	1
Chan, JA; Fogelman, DR; Halperin, DM; Hess, KR; Kulke, MH; Malinowski, P; Ng, CS; Phan, AT; Regan, E; Yao, JC	1
Alonso-Gordoa, T; Apellaniz-Ruiz, M; Capdevila, J; Carrato, A; Casanovas, O; Castellano, D; Díez, JJ; Durán, I; Earl, J; Escudero, P; Fuster, J; García-Carbonero, R; García-Donas, J; Grande, E; Ortega, L; Rodriguez-Antona, C; Sastre, J; Sevilla, I; Teulé, A	1
Kato, S	1
Ha, SY; Heo, JS; Kim, HC; Kim, KM; Kim, ST; Lauwers, G; Lee, J; Park, C; Park, YS	1
Atreya, CE; Bergsland, EK; Cives, M; Coppola, D; Hwang, J; Kelley, RK; Morse, B; Nickerson, M; Strosberg, JR; Valone, T; Venook, A; Weber, T	1
Allen, E; Hanahan, D; Li, L; Miéville, P; Peng, MW; Saghafinia, S; Warren, CM	1
Angulo-Urarte, A; Baselga, J; Casanovas, O; Castel, P; Figueiredo, AM; Graupera, M; Martin, L; Milà-Guasch, M; Monelli, E; Soler, A; Viñals, F	1
Halfdanarson, TR; Naraev, BG; Strosberg, JR	1

Reviews

3 review(s) available for indazoles and Neuroendocrine Tumors

Article	Year
Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors. Pancreas, 2014, Volume: 43, Issue:8 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Differentiation; Chemoradiotherapy; Clinical Trials as Topic; Drugs, Investigational; Everolimus; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Neoplasm Proteins; Neuroendocrine Tumors; Octreotide; Peptides, Cyclic; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radioisotopes; Sirolimus; Somatostatin; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2014
[Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8 Topics: Antibodies, Monoclonal, Humanized; Benzamides; Denosumab; Drug Discovery; Everolimus; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sarcoma; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2015
Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. Oncology, 2012, Volume: 83, Issue:3 Topics: Antineoplastic Agents; Benzenesulfonates; Cell Differentiation; ErbB Receptors; Everolimus; Histone Deacetylases; Humans; Immunologic Factors; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Somatostatin; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2012

Trials

4 trial(s) available for indazoles and Neuroendocrine Tumors

Article	Year
Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours. British journal of cancer, 2013, Sep-17, Volume: 109, Issue:6 Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Female; Humans; Indazoles; Intestinal Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrimidines; Stomach Neoplasms; Sulfonamides; Survival Rate; Treatment Outcome; Young Adult	2013
Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. The Lancet. Oncology, 2015, Volume: 16, Issue:6 Topics: Aged; Carcinoid Tumor; Cohort Studies; Disease-Free Survival; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome	2015
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Cells, Circulating; Neuroendocrine Tumors; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Proportional Hazards Models; Pyrimidines; Sulfonamides; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3	2015
A phase II study of axitinib in advanced neuroendocrine tumors. Endocrine-related cancer, 2016, Volume: 23, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Colonic Neoplasms; Female; Humans; Hypertension; Imidazoles; Indazoles; Intestinal Neoplasms; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Protein Kinase Inhibitors; Rectal Neoplasms; Thymus Neoplasms; Treatment Outcome	2016

Other Studies

4 other study(ies) available for indazoles and Neuroendocrine Tumors

Article	Year
Activity of Entrectinib in a Patient With the First Reported Journal of the National Comprehensive Cancer Network : JNCCN, 2017, Volume: 15, Issue:11 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biopsy; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Drugs, Investigational; Exons; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Intestinal Neoplasms; Intestine, Small; Low Back Pain; Male; Neoplasm Grading; Neuroendocrine Tumors; Oncogene Proteins, Fusion; Palliative Care; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiotherapy; Response Evaluation Criteria in Solid Tumors; Sequence Analysis, RNA; Treatment Outcome	2017
Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors. Oncotarget, 2016, Jan-26, Volume: 7, Issue:4 Topics: Adult; Aged; Biomarkers, Tumor; Cohort Studies; Exome; Female; Genome, Human; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Intestinal Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins B-raf; Pyrimidines; Stomach Neoplasms; Sulfonamides	2016
Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling. Cell reports, 2016, 05-10, Volume: 15, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glucose; Glutamine; Glycolysis; Humans; Imidazoles; Indazoles; Indoles; Intestinal Neoplasms; Lactic Acid; Membrane Transport Proteins; Mice; Models, Biological; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Signal Transduction; Sirolimus; Stomach Neoplasms; Sunitinib; TOR Serine-Threonine Kinases; Up-Regulation	2016
Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Dec-01, Volume: 22, Issue:23 Topics: Animals; Antineoplastic Agents; Benzoxepins; Cell Line, Tumor; Cell Proliferation; Everolimus; Humans; Imidazoles; Indazoles; Liver; Lymphatic Metastasis; Mice; Mice, Inbred C57BL; Neuroendocrine Tumors; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays	2016